Here’s Why Establishment Labs Holdings (ESTA) Soared in Q4

Core Insights - Carillon Eagle Small Cap Growth Fund reported marginal gains in small-cap stocks for Q4 2025, with the Russell 2000 Growth Index returning 13.01% and the Value Index at 12.58% [1] - The firm anticipates a favorable year ahead for equity markets, highlighting potential opportunities in Cyclicals, Healthcare, Information Technology, Financials, and Consumer spending sectors heading into 2026 [1] Company Highlights: Establishment Labs Holdings Inc. (NASDAQ:ESTA) - Establishment Labs Holdings Inc. is recognized as a leading contributor to the fund, focusing on advanced breast implants and reconstructive plastic surgeries [2][3] - The stock closed at $74.60 on February 13, 2026, with an 8.35% return in the past month and a significant 102.73% increase over the past twelve months, giving it a market capitalization of $2.125 billion [2] - The company has seen robust demand following FDA approval in late 2024, with strong brand recognition and clinical advantages over competitors, positioning it for EBITDA profitability by late 2025 or early 2026 [3] - Establishment Labs is expected to achieve cash flow positivity in 2026, supported by a recent FDA application for its implant for primary and revision breast reconstruction [3] Market Position - Establishment Labs Holdings Inc. was held by 29 hedge fund portfolios at the end of Q3 2025, indicating a slight increase from 28 in the previous quarter [4] - Despite its potential, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting that certain AI stocks may offer greater upside potential with less downside risk [4]